News & Updates
Filter by Specialty:
Relacorilant plus nab-paclitaxel prolongs survival in platinum-resistant ovarian cancer
The addition of relacorilant to nab-paclitaxel provides survival benefits in patients with platinum-resistant ovarian cancer (PROC) compared with weekly taxane, according to the results of the phase III ROSELLA study, presented at ESMO Gyn 2025.
Relacorilant plus nab-paclitaxel prolongs survival in platinum-resistant ovarian cancer
03 Sep 2025
Atezolizumab plus chemo, bevacizumab improves survival in R/M cervical cancer
The addition of atezolizumab to first-line chemotherapy plus bevacizumab delivers significant improvements in survival among patients with PD-L1+ or PD-L1‒ persistent, recurrent, or metastatic (R/M) cervical cancer, results of a post hoc analysis of the BEATcc study have shown.
Atezolizumab plus chemo, bevacizumab improves survival in R/M cervical cancer
02 Sep 2025
Real-world data support tirzepatide + hormone therapy for weight loss in postmenopausal women
In postmenopausal women with overweight or obesity, the use of tirzepatide alongside menopause hormone therapy appears to yield better weight loss outcomes than treating with tirzepatide alone, findings from a real-world analysis have shown.
Real-world data support tirzepatide + hormone therapy for weight loss in postmenopausal women
21 Aug 2025
Can pregnant, lactating people use lenacapavir to prevent HIV infection?
The use of lenacapavir is highly efficacious in pregnant and lactating people (PLP), with zero participants acquiring HIV, as shown by the results of the PURPOSE 1 study.